Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes
Annals of Internal Medicine · 2023-12 · 176 (12) · 1606-1616
DOI: 10.7326/m23-1023 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of Internal Medicine, 2023-12. Verfasst von Rajiv Agarwal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis, Indiana (R.A.). Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Renal Insufficiency, Chronic, Renal Insufficiency. Die Arbeit wurde bisher 112-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Bayer.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces cardiovascular and kidney failure outcomes. Finerenone also lowers the urine albumin-to-creatinine ratio (UACR). Whether finerenone-induced change in UACR mediates cardiovascular and kidney failure outcomes is unknown. OBJECTIVE: To quantify the proportion of kidney and cardiovascular risk reductions seen over a 4-year period mediated by a change in kidney injury, as measured by the change in log UACR between baseline and month 4. DESIGN: Post hoc mediation analysis using pooled data from 2 phase 3, double-blind trials of finerenone. (ClinicalTrials.gov: NCT02540993 and NCT02545049). SETTING: Several clinical sites in 48 countries. PATIENTS: 12 512 patients with CKD and T2D. INTERVENTION: Finerenone and placebo (1:1). MEASUREMENTS: Separate mediation analyses were done for the composite kidney (kidney failure, sustained ≥57% decrease in estimated glomerular filtration rate from baseline [approximately a doubling of serum creatinine], or kidney disease death) and cardiovascular (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) outcomes. RESULTS: At baseline, median UACR was 514 mg/g. A 30% or greater reduction in UACR was seen in 3338 (53.2%) patients in the finerenone group and 1684 (27.0%) patients in the placebo group. Reduction in UACR (analyzed as a continuous variable) mediated 84% and 37% of the treatment effect on the kidney and cardiovascular outcomes, respectively. When change in UACR was analyzed as a binary variable (that is, whether the guideline-recommended 30% reduction threshold was met), the proportions mediated for each outcome were 64% and 26%, respectively. LIMITATION: The current findings are not readily extendable to other drugs. CONCLUSION: In patients with CKD and T2D, early albuminuria reduction accounted for a large proportion of the treatment effect against CKD progression and a modest proportion of the effect against cardiovascular outcomes. PRIMARY FUNDING SOURCE: Bayer AG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis, Indiana (R.A.).
- Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana (W.T.).
- Data Science and Analytics, Bayer PLC, Reading, United Kingdom (A.E.F.).
- Bayer U.S. LLC, Cambridge, Massachusetts (Y.M.K.F.).
- Department of Internal Medicine, University of Texas Southwestern Medicine, Dallas, Texas (R.T.).
- Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California (S.K.).
ORCID-Profile: Rajiv Agarwal, Wanzhu Tu, Youssef M K Farag, Robert Toto, Luis M Ruilope, Peter Rossing, Gerasimos Filippatos, Stefan D Anker
Förderung
- Bayer
Zitieren
APA
Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., Pitt, B., Filippatos, G., Anker, S. D., Bakris, G. L., & FIDELIO-DKD and FIGARO-DKD Investigators (2023). Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes. Annals of Internal Medicine, 176(12), 1606-1616. https://doi.org/10.7326/m23-1023
Vancouver
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, et al. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes. Annals of Internal Medicine. 2023;176(12):1606-1616. doi:10.7326/m23-1023
BibTeX
@article{Agarwal2023,
author = {Agarwal, Rajiv and Tu, Wanzhu and Farjat, Alfredo E and Farag, Youssef M K and Toto, Robert and Kaul, Sanjay and Lawatscheck, Robert and Rohwedder, Katja and Ruilope, Luis M and Rossing, Peter and Pitt, Bertram and Filippatos, Gerasimos and Anker, Stefan D and Bakris, George L and FIDELIO-DKD and FIGARO-DKD Investigators, FIDELIO-DKD and FIGARO-DKD Investigators},
title = {Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes},
journal = {Annals of Internal Medicine},
year = {2023},
volume = {176},
number = {12},
pages = {1606--1616},
doi = {10.7326/m23-1023}
}
EUVIMED